Novel Approaches to Depression Treatment: Integrating Pharmacological and Non-Pharmacological Strategies

References

[1] and Adherence, 11, 1859–1868.

[2] Rush, A. J., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. The American Journal of Psychiatry, 163(11), 1905-1917.

[3] McAllister-Williams, R. H., et al. (2020). The identification, assessment and management of difficult-to-treat depression: An international consensus statement. Journal of Affective Disorders, 267, 264-282.

[4] Rush, A. J., et al. (2019). Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive. Australian & New Zealand Journal of Psychiatry, 53, 109-118.

[5] Elias, E., et al. (2022). Novel pharmacological approaches to the treatment of depression. Life (Basel, Switzerland), 12(2), 196.

[6] Crane, G. E. (1957). Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating diseases. Psychiatric Research Reports, 8, 142-152.

[7] Dunlop, E., DeFelice, E. A., Bergen, J. R., et al. (1965). The relationship between MAO inhibition and improvement of depression: Preliminary results with intravenous modaline sulfate (W3207B). Psychosomatics, VI, 1-7.

[8] Amsterdam, J. D., & Chopra, M. (2001). Monoamine oxidase inhibitors revisited. Psychiatric Annals, 31, 361-370.

[9] Pare, C. M. B. (1985). The present status of monoamine oxidase inhibitors. British Journal of Psychiatry, 146, 576-584.

[10] Baker, G. B., Coutts, R. T., McKenna, K. F., et al. (1992). Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: A review. Journal of Psychiatric Neuroscience, 17, 206-214.

[11] Cusack, B., Nelson, A., & Richelson, E. (1994). Binding of antidepressants to human brain receptors: Focus on newer generation compounds. Psychopharmacology, 114(4), 559-565.

[12] Aree, T. (2020). Supramolecular complexes of ²-cyclodextrin with clomipramine and doxepin: Effect of the ring substituent and component of drugs on their inclusion topologies and structural flexibilities. Pharmaceuticals, 13, 278.

[13] Ansseau, M., et al. (1984). Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depression. Journal of Affective Disorders, 7, 287-296.

[14] Hirschfeld, R. M. A. (2000). History and evolution of the monoamine hypothesis of depression. Journal of Clinical Psychiatry, 61(Suppl. 6), 4-6.

[15] Donoghue, J., Tylee, A., & Wildgust, H. (1996). Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993–5. BMJ, 313, 861–862.

[16] National Collaborating Centre for Mental Health. (2010). Depression: The treatment and management of depression in adults (Updated edition). Leicester, UK: British Psychological Society

[17] Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. Journal of Neuroscience, 20(24), 9104–9110.

[18] Ji, O. S., Karalis, P. G., Daas, M., & Condon, J. (2019). Gynecomastia associated with citalopram. Primary Care Companion to CNS Disorders, 21, 27311

[19] Xu, D., et al. (2020). The antidepressant-like effects of fluvoxamine in mice involve the mTOR signaling in the hippocampus and prefrontal cortex. Psychiatry Research, 285, 112708.

[20] Papakostas, G. I. (2009). Serotonin norepinephrine reuptake inhibitors: Spectrum of efficacy in major depressive disorder. Primary Psychiatry, 16(5, Suppl. 4), 16–24.

[21] Fanelli, D., et al. (2021). New serotonin-norepinephrine reuptake inhibitors and their anesthetic and analgesic considerations. Neurology International, 13, 497–509.

[22] Lavender, E., Hirasawa-Fujita, M., & Domino, E. F. (2020). Ketamine’s dose related multiple mechanisms of actions: dissociative anesthetic to rapid antidepressant. Behavioural Brain Research, 390, 112631.

[23] MacDonald, J. F., Miljkovic, Z., & Pennefather, P. (1987). Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. Journal of Neurophysiology, 58, 251–266.

[24] Kim, J. W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023). Bridging rapid and sustained antidepressant effects of ketamine. Trends in Molecular Medicine, 29, 364–375.

[25] Domino, E.F. (2020). Ketamine’s dose related multiple mechanisms of actions: dissociative anesthetic to rapid antidepressant. Behavioral Brain Research, 390, 112631.

[26] Kim, J.W., Suzuki, K., Kavalali, E.T., & Monteggia, L.M. (2023). Bridging rapid and sustained antidepressant effects of ketamine. Trends in Molecular Medicine, 29, 364–375

[27] American Psychological Association. (2010). Publication manual of the American Psychological Association (6th ed.)

[28] N2O: Steinberg, A. The use of naloxone to counteract opioid-induced pruritus; Mayo Clinic Proceedings; 24(7)109

[29] Berger, J., & Moller, D. E. (2002). The mechanisms of action of PPARs. Annual Review of Medicine, 53(1), 409-435.

[30] Jasper, M. S., & Engeland, W. C. (1994). Splanchnic neural activity modulates ultradian and circadian rhythms in adrenocortical secretion in awake rats. Neuroendocrinology, 59(2), 97–109.

[31] Cascio, C. S., Shinsako, J., & Dallman, M. F. (1987). The suprachiasmatic nuclei stimulate evening ACTH secretion in the rat. Brain Research, 423(1-2), 173–179.

[32] Szafarczyk, A., Alonso, G., Ixart, G., Malaval, F., & Assenmacher, I. (1985). Diurnal-stimulated and stress-induced ACTH release in rats is mediated by ventral noradrenergic bundle. American Journal of Physiology, 249(2 Pt 1), E219–E226.

[33] Beaulieu, S., Pelletier, G., Vaudry, H., & Barden, N. (1989). Influence of the central nucleus of the amygdala on the content of corticotropin-releasing factor in the median eminence. Neuroendocrinology, 49(3), 255–261.

[34] Beaulieu, S., De Paolo, T., Côté, J., & Barden, N. (1987). Participation of the central amygdaloid nucleus in the response of adrenocorticotropin secretion to immobilization stress: Opposing roles of the noradrenergic and dopaminergic systems. Neuroendocrinology, 45(1), 37–46.

[35] Jacobson, L., & Sapolsky, R. (1991). The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocrine Reviews, 12(2), 118–134. doi:10.1210/edrv-12-2-118

[36] Reul, J. M. H. M., & de Kloet, E. R. (1985). Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology, 117(6), 2505–2512. doi:10.1210/endo-117-6-2505

[37] Dinan, T. G., & Cryan, J. F. (2017). Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration. The Journal of Physiology, 595(2), 489-503

[38] Bercik, P., Verdu, E. F., Foster, J. A., et al. (2010). Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology, 139(6), 2102-2112.

[39] O’Sullivan, E., Barrett, E., Grenham, S., Fitzgerald, P., Stanton, C., Ross, R. P., ... Dinan, T. G. (2011). BDNF expression in the hippocampus of maternally separated rats: Does Bifidobacterium breve 6330 alter BDNF levels? Beneficial Microbes, 2(3), 199–207.

[40] Parada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., et al. (2019). Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Frontiers in Immunology.

[41] Foster, J. A., et al. (2017). Stress & the gut-brain axis: Regulation by the microbiome. Neurobiology of Stress.

[42] Sudo, N., et al. (2004). Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. Journal of Physiology, 558(1), 263–275.

[43] Keller, J., et al. (2017). HPA axis in major depression: Cortisol, clinical symptomatology and genetic variation predict cognition. Molecular Psychiatry, 22(4), 527–536.

[44] Winter, G., et al. (2018). Gut microbiome and depression: What we know and what we need to know. Reviews in the Neurosciences, 29(6), 629–643.

[45] Kamada, N., et al. (2013). Role of the gut microbiota in immunity and inflammatory disease. Nature Reviews Immunology, 13(5), 321–335.

[46] Hofmann, A., Frey, A., Ott, H., Petr Zilka, T., & Troxler, F. (1958). Elucidation of the structure and the synthesis of psilocybin. Experientia, 14, 397–399.

[47] Hofmann, A., Heim, R., Brack, A., & Kobel, H. (1958). Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim. Experientia, 14, 107–109.

[48] Buchborn, T., Schroder, H., Hollt, V., & Grecksch, G. (2014). Repeated lysergic acid diethylamide in an animal model of depression: normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling. Journal of Psychopharmacology, 28(6), 545–552.

[49] Carhart-Harris, R. L., Erritzoe, D., Williams, T., et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America, 109(6), 2138–2143.

[50] Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 29(3), 280–288.

[51] Gasser, P., Holstein, D., Michel, Y., et al. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. Journal of Nervous and Mental Disease, 202(7), 513–520.

[52] Ross, S., et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180.

[53] Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620.

[54] O'Cleirigh, C., Safren, S. A., Taylor, S. W., Goshe, B. M., Bedoya, C. A., Marquez, S. M., Boroughs, M. S., & Shipherd, J. C. (2019). Cognitive Behavioral Therapy for Trauma and Self-Care (CBT-TSC) in Men Who have Sex with Men with a History of Childhood Sexual Abuse: A Randomized Controlled Trial. AIDS Behavior, 23(9), 2421-2431

[55] Sahranavard, S., Esmaeili, A., Salehiniya, H., & Behdani, S. (2019). The effectiveness of group training of cognitive behavioral therapy-based stress management on anxiety, hardiness and self-effichijqrvwy�‘’“•—˜™¤¦¿ÀÁÂëÜÑĺĮ¡º®–ˆzzˆnbbbbVGh^~ h˜gCJOJQJaJh^~ CJOJQJaJh.c�hÿ|Õ6�OJQJh.c�h.c�6�OJQJh.c�h.c�6�H*OJQJh.c�hÿ|Õ6�H*OJQJh^~ hÿ|ÕOJQJh^~ h.c�OJPJQJh^~ h.c�H*OJQJh.c�OJPJQJhJ\ëh.c�OJPJQJh^~ h^~ OJQJhJ\ëhÿ|ÕCJ(OJQJaJ((hJ\ëhÿ|ÕCJ(OJPJQJaJ(nH @tH @ij’ÀÁÂ./ ¡®¯cd##$õõçõÙǽ½½½¨½½½½½½$ &F „7„Éý¤^„7`„Éýa$gd.c� $¤a$gd.c�„ñÿ„ dð¤]„ñÿ^„ gd^~ [Some characters in this reference could not be displayed correctly — please refer to the published PDF for the full reference.]

[56] [Some characters in this reference could not be displayed correctly — please refer to the published PDF for the full reference.]

@article{1706023,
      author = {Sakshi Gupta, Dr. Manish Kumar Shakya},
      title = {Novel Approaches to Depression Treatment: Integrating Pharmacological and Non-Pharmacological Strategies},
      journal = {Iconic Research And Engineering Journals},
      year = {2024},
      volume = {8},
      number = {1},
      pages = {100-112},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1706023.pdf},
      abstract = {Major depressive illness (MDD) is a persistent and incapacitating Psychological disorder affecting more than 280 million people worldwide. Depression is approximately 50% more frequent compared to men in women. Approximately 10% of women worldwide suffer from antenatal and postnatal depression. More than 700,000 people commit suicide annually. When it comes to causes of death, suicide ranks fourth among those between the ages of 15 and 29. Depression is characterized as an ongoing feeling of melancholy, despair, and a loss of interest in life, which affects one's thoughts, emotions, and general well-being. Antidepressants based on monoamines were initially developed for severe depression. However, due to delayed therapeutic effectiveness and one-third of patients showing partial response to single-drug therapy, alternative methods must be explored. Recent advancements include complementary medications and nonpharmacological treatments. This overview traces the historical development of antidepressants from their inception to modern advancements. Today's pharmacological techniques include targeting receptors like ketamine and GABA and addressing biological processes such as the HPA axis and gut microbiota. Novel non-pharmacological approaches like psilocybin therapy, CBT, ECT, TMS, and lifestyle interventions offer diverse treatment options for depression.},
      keywords = {Antidepressant , Major Depressive Disorder, Non-Pharmacological Therapy, Pharmaceutical technique},
      month = {July},
  }